Status:
RECRUITING
68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
Lead Sponsor:
Peking University First Hospital
Conditions:
Carbonic Anhydrase IX
PET-CT
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 68Ga-C1 in PET/CT imaging in clear cell renal cell carcinoma patients. It will also learn about the s...
Detailed Description
Carbonic anhydrase IX (CAIX) is a transmembrane protein which is highly expressed in approximately 95% of clear cell renal cell carcinomas, and it is closely related to tumor progression, patients pro...
Eligibility Criteria
Inclusion
- Signed written informed consent；
- Age ≥18；
- Patients with confirmed or suspected clear cell renal cell carcinoma;
- Expected survival ≥6 months.
Exclusion
- Renal mass is known to be a metastasis of another primary tumor;
- Have other malignancies that require treatment;
- Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks;
- Renal insufficiency with glomerular filtration rate (GFR) ≤ 60 mL/min/1.73 m²;
- Pregnant and lactating women or female patients plan to become pregnant within 6 months;
- Uncontrolled psychiatric disorders;
- Vulnerable population (e.g., being in detention) or have a serious non-malignant disease (e.g., infectious disease, autoimmune disease, or metabolic disease).
Key Trial Info
Start Date :
July 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06519760
Start Date
July 30 2024
End Date
December 31 2026
Last Update
November 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034